FCER1A and neoplasm: Anti-tumour IgE antibodies can engage various immune effector cells such as mast cells and basophils expressing high levels of tetrameric FcεRI (αβγ2), and monocytes and eosinophils that express trimeric FcεRI (αγ2) at lower levels.